Literature DB >> 17132213

Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.

Fumiaki Yamashita1, Hisakazu Ohtani, Noriko Koyabu, Fumihiko Ushigome, Hiroki Satoh, Hideyasu Murakami, Takeshi Uchiumi, Takanori Nakamura, Michihiko Kuwano, Masayuki Tsujimoto, Yasufumi Sawada.   

Abstract

Human organic anion transporter 4 (OAT4) is the only member of the OAT family that is expressed in the placenta and also expressed in kidney. Although OAT4 has been shown to transport certain organic anions as well as other members of the OAT family, fewer numbers of substrates have been identified for OAT4 compared with OAT1 and OAT3, suggesting that the substrate specificity of OAT4 is greater than other OAT members. However, the substrate specificity of OAT4 remains to be investigated in detail. The aim of this study was to examine the effects of various drugs on the OAT4-mediated transport of estrone-3-sulfate, a typical substrate of OAT4, by using human embryonic kidney cells stably transfected with OAT4 (HEK-OAT4). HEK-OAT4 cells exhibited concentration-dependent uptake of estrone-3-sulfate, with a K(m) value of 20.9+/-3.53 microM. Dehydroepiandrosterone sulfate and probenecid potently inhibited estrone-3-sulfate uptake. We also searched for the potential inhibitors of OAT4 and identified candesartan, candesartan cilexetil, losartan, losartan carboxyl (EXP3174) and valsartan as inhibitors of OAT4, with K(i) values of 88.9, 135.2, 24.8, 13.8 and 19.6 microM, respectively. The above angiotensin II receptor antagonists and leukotriene receptor antagonists share a common structural feature, that is the tetrazole group. Although pranlukast is devoid of anionic motifs other than the tetrazole group, it potently inhibited the OAT4-mediated uptake of estrone-3-sulfate, indicating that a tetrazole group may be one important structural feature in substrate recognition by OAT4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132213     DOI: 10.1211/jpp.58.11.0011

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.

Authors:  Masanobu Sato; Takashi Iwanaga; Hideaki Mamada; Toshio Ogihara; Hikaru Yabuuchi; Tomoji Maeda; Ikumi Tamai
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

Review 2.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates.

Authors:  James E Shima; Takafumi Komori; Travis R Taylor; Doug Stryke; Michiko Kawamoto; Susan J Johns; Elaine J Carlson; Thomas E Ferrin; Kathleen M Giacomini
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

Review 5.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

6.  Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4.

Authors:  May Fern Toh; Wonmo Suh; Haoxun Wang; Peter Zhou; Longqin Hu; Guofeng You
Journal:  Int J Biochem Mol Biol       Date:  2016-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.